Innovationen verändern die Welt

Der Beitrag von Arzneimittelinnovationen in der Therapie psychischer Erkrankungen?

authored by: J. M. Graf Von Der Schulenburg, A. Kuhlmann
Abstract: Psychiatric disease constitutes a large burden for society. The social costs of psychiatric disorders surpass cancer and cardiac diseases. Many patients affected by psychiatric disease are still in the working age, thus causing high indirect illness costs. Despite the substantial advances in the treatment of psychiatric patients and the development of new drugs in recent years, there is still considerable room for improvement in treatment outcomes, compliance and side-effect profiles in psychiatric therapies. Hence, there is a need for new innovative psychiatric drugs. However, long development times and low success rates compared to other therapeutic areas as well as accelerating cost containment measures hinder the development of innovative psychiatric drugs. In order to reduce the time and costs of developing innovative drugs, the research and development process of psychiatric drugs has to be rationalized. In addition regulatory authorities and sickness funds should reflect the increasing importance of psychiatric disorders and the need for innovative therapies. Only then will the development of new drugs in the field of psychiatric disorders progress according to its medical and economic importance.
Organisation(s): Center for Health Economics Research Hannover (CHERH)
Type: Article
Journal: Gesundheitsokonomie und Qualitatsmanagement
Volume: 18
Pages: 244-252
No. of pages: 9
ISSN: 1432-2625
Publication date: 10.2013
Publication status: Published
Peer reviewed: Yes
ASJC Scopus subject areas: Health Policy
Sustainable Development Goals: SDG 3 - Good Health and Well-being
Electronic version(s): https://doi.org/10.1055/s-0033-1355492 (Access: Closed)